Plasma Levels of Tumor Necrosis Factor and Endothelial Response in Patients with Chronic Arterial Obstructive Disease or Raynaud's Phenomenon

Abstract

Tumor necrosis factor alpha (TNF-alpha) is a cytokine that affects endothelial cells' function by changing their antithrombotic potential to a net procoagulant effect. Only a few data have so far been reported for the pathophysiologic role of TNF in vascular diseases in the involvement of microvessels and/or macrovessels and a prothrombotic state. In the present study the authors evaluated plasma TNF (and interleukin-1) levels in 20 patients with chronic arterial obstructive disease (CAOD) with intermittent claudi cation and 10 CAOD patients with more severe disease (pain at rest/skin ulcers). In addition, they studied 10 patients with Raynaud's phenomenon (RP), suspected to be secondary to a collagen disease. The control group consisted of 20 subjects matched for sex and age with the three groups of patients. TNF levels were assayed by enzyme-linked immunosorbent assay

The antigen levels of von Willebrand factor (vWF), tissue plasminogen activator (t- PA), and its inhibitor (PAI) were also determined as markers of release from the endothe lium, while the fragment 1+2 of prothrombin (F1+2) and thrombin-antithrombin III (TAT) complexes were assessed as indexes of systemic thrombin generation.

TNF levels were significantly higher in both groups of CAOD patients than in controls or RP patients, and the same was true for vWF. t-PA was significantly higher only in the CAOD subjects with more severe disease. No differences among groups were seen in PAI antigen/activity or thrombin generation. When data were corrected for age, TNF no longer differentiated CAOD patients from controls and RP subjects. There were strong direct correlations between TNF and age (r=0.57, P=0.0001); TNF and t-PA (r=0.43, P=0.002); and TNF and vWF (r=0.52, P=0.0001). The association of TNF with vWF was indepen dent of other variables. The present study suggests that TNF plays an important role in the pathophysiology of arterial diseases of atherosclerotic origin, especially during aging.

Get full access to this article

View all access options for this article.

References

Kahaleh MB , Osborn I. , Le Roy EC : Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and Raynaud's phenomenon. Ann Intern Med 94:482-484, 1981.

Cimminiello C. , Milani M. , Uberti T. , et al: Differential diagnosis of Raynaud phenomenon. The role of t-PA and PAI. Fibrinolysis 1988, 2(S1):abstract 231.

Cimminiello C. , Milani M. , Uberti T. , et al: t-PA, PAI, and protein C before and after vascular occlusion of the upper limb in patients with Raynaud's phenomenon . Angiology 43:231-238, 1991.

Nawroth PP , Stern DM : Modulation of endothelial cell hemostatic properties by tumor necrosis factor . J Exp Med 163:740-745, 1986.

Bevilacqua MP , Pober JS , Majeau GR , et al: Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160:618-623, 1984.

Bevilacqua MP , Pober JS , Majeau GR , et al: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelial cell: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 82:4533-4537, 1986 .

Speiser W. , Speiser P. , Minor E. , et al: Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localization of vessel disease and risk factors . Thromb Res 59:77-86, 1990.

Gallino A. , Haeberli A. , Straub PW : Fibronopeptide A excretion in urine in patients with atherosclerotic artery disease. Thromb Res 39:237-244, 1987.

Schleef RR , Bevilacqua MP , Sawdey M. , et al: Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797-5803, 1988.

10.

Paleolog EM , Grossman DC , McVey JH , et al: Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 75:688-694, 1990.

11.

Wouda AA : Raynaud's phenomenon: Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up. Acta Med Scand 201:519-523, 1987.

12.

Cimminiello C. , Milani M. , Pietra A. , et al: Deficient fibrinolytic response in patients with Raynaud's Phenomenon and its correction with defibrotide. Semin Thromb Hemost 17(S1):106-111, 1991.

13.

Kobayashi M. , Shimade K. , Onawa T. : Human recombinant interleukin 1β and tumor necrosis factor α-mediated suppression of heparin-like compounds and cultured porcine aortic endothelial cells. J Cell Physiol 144:383-390, 1990.

14.

Conway EM , Bach R. , Rosenberg RD , et al: Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 53:221-231, 1989.

15.

van der Poll T. , Büller HR , Ten Cate H. , et al: Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322:1622-1627, 1990.

16.

Bauer KA , Ten Cate H. , Borzegar S. , et al: Tumor necrosis factor infusions have precoagulant effect on the hemostatic mechanism of humans. Blood 74:165-172, 1989.

17.

van Hinsbergh VWM , Bauer KA , Kooistra T. , et al: Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin (ogen) degradation products. Blood 76:2284-2289, 1990 .

18.

van Hinsbergh Vwm , Kooistra T. , van den Berg EA , et al: Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 72:1467-1473, 1988.

19.

van der Poll T. , van Deventer Sjh , PasterKamp G. , et al: Tumor necrosis factor induces von Willebraud factor release in healthy humans. Thromb Haemostas 67:623-626, 1992.

20.

Girardin E. , Grau GE , Dayer JM , et al: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397-400, 1988.

21.

Waage A. , Halstensen A. , Espevik T. : Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355-357, 1987.

22.

Levine B. , Kalman J. , Mayer L. , et al: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236-241, 1990.

23.

Maury Cpj , Teppo AM : Tumor necrosis factor in the serum of patients with systemic lupus erythematosus . Arthritis Rheum 22:146-150, 1989.

24.

Saxne T. , Palladino MA Jr , Heinegard D. , et al: Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041-1045, 1988.

25.

Whiteneedleman B. , Wigley FM , Stair RW : Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α and interferon levels in sera from patients with scleroderma. Arthritis Rheum 35:67-72, 1992.